ChromaDex Corp (NAGE) Stock Forecast & Price Target

Niagen Bioscience is a leader in NAD+ science, with a clinically proven and unique product, Tru Niagen, that has shown to increase NAD+ levels effectively. The company's strong financial profile and diversified growth opportunities, such as expanding into the skincare and injectable markets, and the potential launch of a telehealth platform with a pen-like autoinjector, indicate a promising outlook for continued revenue growth. Additionally, the recent USP monograph for nicotinamide riboside chloride and expansion into new product offerings, as well as the potential for new uses in rare diseases, highlight the company's strong intellectual property portfolio and potential for future growth.

Niagen Bioscience is heavily reliant on consumer interest in health and wellness trends for their growth, and while they have differentiated themselves from their competitors by using science-backed innovation, there may not be enough demand to sustain their growth projections. Additionally, the current macro environment may also have a negative impact on consumer spending, potentially leading to lower sales for Niagen. This is reflected in our revised 1Q26 sales estimate of $30.6M and our FY26 sales estimate of $147.3M, which are only marginal increases from the previous year.